Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
59pct
3d open
vs 9,698 other HR bills in the 117th — cohort avg 63d
Cameron's Law This bill increases the rate of the tax credit for clinical testing expenses for rare diseases or conditions from 25% to 50% (orphan drug tax credit). The bill also requires the Centers for Disease Control and Prevention to complete a study to evaluate the feasibility of enhancing and expanding the infrastructure to track the epidemiology of rare diseases or conditions.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (10)
Referred to the Subcommittee on Health.
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2022 · fourth_quarter · Taxation/Internal Revenue Code
H.R. 2623 - Camerons Law H.R. 5376 - Build Back Better Act Issues related to the Orphan Drug Tax Credit Issues related to the deduction of research and development expenditures Issues related to corporate and international tax reform S. 749/H.R 1304 - American Innovation and Jobs Act
Client expense: $1,170,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Client expense: $250,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Taxation/Internal Revenue Code
Issues generally related to the Orphan Drug Tax Credit, including provisions in H.R. 2623, Camerons Law and H.R. 5376, Build Back Better Act.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
Issues related to the development of therapies for rare diseases and sleep disorders. Drug pricing. Access to non-controlled medications. PDUFA Reauthorization. H.R.6000 - Cures 2.0 Act. FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169). H.R.5585 - Advanced Research Project Agency-Health (ARPA-H) Act. H.R.6963 - Accelerated Approval Integrity Act of 2022. H.R.2623 - Camerons Law. H.R.7667 - Food and Drug Amendments of 2022. S.4348 - FDASLA Act of 2022. H.R.6833 - Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180). H.R.8641 - Orphan Drug COVID-19 Mitigation Act of 2022. H.R.1730/S.670 - Speeding Therapy Access Today (STAT) Act of 2021. Issues related to raising awareness of World Narcolepsy Day.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Taxation/Internal Revenue Code
Issues related to the development of therapies for rare diseases and sleep disorders. Drug pricing. Access to non-controlled medications. PDUFA Reauthorization. H.R.6000 - Cures 2.0 Act. FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169). H.R.5585 - Advanced Research Project Agency-Health (ARPA-H) Act. H.R.6963 - Accelerated Approval Integrity Act of 2022. H.R.2623 - Camerons Law. H.R.7667 - Food and Drug Amendments of 2022. S.4348 - FDASLA Act of 2022. H.R.6833 - Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180). H.R.8641 - Orphan Drug COVID-19 Mitigation Act of 2022. H.R.1730/S.670 - Speeding Therapy Access Today (STAT) Act of 2021.
Client expense: Not reported · Firm income: $50,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
H. RES. 1330 H.R. 6216/S. 3389, the Sickle Cell Disease Comprehensive Care Act H.R. 8855/S. 4866, the Sickle Cell Disease Treatment Centers Act of 2022 S. 1644/H.R. 3761, the Promising Pathway Act S. 373/H.R. 4472, the BENEFIT Act of 2021 H.R.2623, Camerons Law
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Client expense: $250,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R.1730/S.670, The Speeding Therapy Access Today (STAT) Act of 2021; H.R.2617, Consolidated Appropriations Act, 2023.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021;
Client expense: Not reported · Firm income: $20,000
2022 · fourth_quarter · Taxation/Internal Revenue Code
The reduction, stabilization and/or change of the tax credit for the Orphan Drug Act and how it affects plasma protein therapies and their innovation, also H.R. 2623.
Client expense: $140,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · third_quarter · Taxation/Internal Revenue Code
H.R. 2623 - Camerons Law H.R. 5376 - Build Back Better Act Issues related to the Orphan Drug Tax Credit Issues related to the deduction of research and development expenditures Issues related to corporate and international tax reform S. 749/H.R 1304 - American Innovation and Jobs Act
Client expense: $930,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Health Issues
Issues related to the development of therapies for rare diseases and sleep disorders. Drug pricing. Access to non-controlled medications. PDUFA Reauthorization. H.R.6000 - Cures 2.0 Act. FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169). H.R.5585 - Advanced Research Project Agency-Health (ARPA-H) Act. H.R.6963 - Accelerated Approval Integrity Act of 2022. H.R.2623 - Camerons Law. H.R.7667 - Food and Drug Amendments of 2022. S.4348 - FDASLA Act of 2022. H.R.6833 - Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180). H.R.8641 - Orphan Drug COVID-19 Mitigation Act of 2022. H.R.1730/S.670 - Speeding Therapy Access Today (STAT) Act of 2021. Issues relatred to raising awareness of World Narcolepsy Day.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Taxation/Internal Revenue Code
Issues related to the development of therapies for rare diseases and sleep disorders. Drug pricing. Access to non-controlled medications. PDUFA Reauthorization. H.R.6000 - Cures 2.0 Act. FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169). H.R.5585 - Advanced Research Project Agency-Health (ARPA-H) Act. H.R.6963 - Accelerated Approval Integrity Act of 2022. H.R.2623 - Camerons Law. H.R.7667 - Food and Drug Amendments of 2022. S.4348 - FDASLA Act of 2022. H.R.6833 - Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180). H.R.8641 - Orphan Drug COVID-19 Mitigation Act of 2022. H.R.1730/S.670 - Speeding Therapy Access Today (STAT) Act of 2021.
Client expense: Not reported · Firm income: $50,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Health Issues
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021;
Client expense: Not reported · Firm income: $20,000
2022 · third_quarter · Taxation/Internal Revenue Code
H.R. 2623 - Camerons Law H.R. 5376 - Build Back Better Act Issues related to the Orphan Drug Tax Credit Issues related to the deduction of research and development expenditures Issues related to corporate and international tax reform S. 749/H.R 1304 - American Innovation and Jobs Act
Client expense: $910,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Health Issues
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R.1730/S.670, The Speeding Therapy Access Today (STAT) Act of 2021.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Taxation/Internal Revenue Code
The reduction, stabilization and/or change of the tax credit for the Orphan Drug Act and how it affects plasma protein therapies and their innovation, also H.R. 2623.
Client expense: $120,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · third_quarter · Health Issues
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Client expense: $250,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Taxation/Internal Revenue Code
H.R. 2623 - Camerons Law; H.R. 5376 - Build Back Better Act; Issues related to the Orphan Drug Tax Credit; Issues related to the deduction of research and development expenditures Issues related to corporate and international tax reform
Client expense: $1,270,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Taxation/Internal Revenue Code
The reduction, stabilization and/or change of the tax credit for the Orphan Drug Act and how it affects plasma protein therapies and their innovation, also H.R. 2623.
Client expense: $140,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · first_quarter · Taxation/Internal Revenue Code
H.R. 2623 - Camerons Law; H.R. 5376 - Build Back Better Act; Issues related to the Orphan Drug Tax Credit; Issues related to the deduction of research and development expenditures Issues related to corporate and international tax reform
Client expense: $1,480,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Health Issues
H.R. 5376, the Build Back Better Act H.R. 6000, Cures 2.0 Act H.R. 2623, Camerons Law
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Health Issues
H.R.5376 - Build Back Better Act H.R.2623 - Camerons Law H.R.6160 - Access to Rare Indications Act of 2021 H.R.1184 - Helping Experts Accelerate Rare Treatments Act of 2021 2416- New Opportunities for Value that Extend Lives Act of 2021 S.350- Newborn Screening Saves Lives Reauthorization Act of 2021 H.R.6963 - Accelerated Approval Integrity Act of 2022 H.R.6996 - Accelerating Access for Patients Act of 2022
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Taxation/Internal Revenue Code
The reduction, stabilization and/or change of the tax credit for the Orphan Drug Act and how it affects plasma protein therapies and their innovation, also H.R. 2623.
Client expense: $240,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2021 · fourth_quarter · Taxation/Internal Revenue Code
HR 2623: CAMERON'S LAW; ALL PROVISIONS OF THE BILL HR 5376: BUILD BACK BETTER ACT; PROVISIONS RELATED TO SECTIONS 138121, 138126, 138127, 138141, 139001, 139101, 139102, 139201, AND THE ORPHAN DRUG ACT TAX CREDIT
Client expense: $270,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · fourth_quarter · Health Issues
H.R. 5376, the Build Back Better Act H.R. 6000, Cures 2.0 Act H.R. 2623, Camerons Law H.R. 482/S. 350, the Newborn Screening Saves Lives Reauthorization Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2021 · fourth_quarter · Health Issues
H.R. 6000, Cures 2.0 Act H.R. 5376, the Build Back Better Act H.R. 2623, Camerons Law H.R. 482/ S. 350, the Newborn Screening Saves Lives Reauthorization Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · fourth_quarter · Taxation/Internal Revenue Code
The reduction, stabilization and/or change of the tax credit for the Orphan Drug Act and how it affects plasma protein therapies and their innovation, also H.R. 2623.
Client expense: $140,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS)
2021 · third_quarter · Taxation/Internal Revenue Code
HR 2623: CAMERON'S LAW; ALL PROVISIONS OF THE BILL HR 5376: BUILD BACK BETTER ACT; PROVISIONS RELATED TO SECTION 138141 GENERAL DISCUSSIONS REGARDING THE ORPHAN DRUG ACT
Client expense: $190,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · third_quarter · Health Issues
H.R. 1730/S. 670, the Speeding Therapy Access Today (STAT) Act H.R. 2623, Camerons Law MACPAC Accelerated Approval Pathway Recommendations Cures 2.0 (not introduced yet)
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · third_quarter · Health Issues
H.R. 5: Equality Act H.R. 724: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2021 - Provisions related to FDA drug approval process H.R. 832: Safe and Affordable Drugs from Canada Act of 2021 - Provisions related to prescription drug importation H.R. 853: Closing Loopholes for Orphan Drugs Act - Provisions related to 340B drug discount program H.R. 1400: COVID-19 Health Disparities Action Act of 2021 - Provisions related to COVID-19 vaccines H.R. 1873: Advancing Education on Biosimilars Act of 2021 - Provisions related to biologics and biosimilar products H.R. 2181: Affordable and Safe Prescription Drug Importation Act - Provisions related to prescription drug importation H.R. 2347: Strengthening the Vaccines for Children Program Act of 2021 - Provisions related to COVID-19 vaccines H.R. 2565: FDA Modernization Act of 2021 - Provisions related to FDA policy and health research H.R. 2623: Camerons Law - Provisions related to orphan drugs H.R. 2815: BIOSIM Act - Provisions related to biosimilars and prescription drug pricing H.R. 2831: Prompt Approval of Safe Generic Drugs Act- Provisions related to FDA policy and approvals H.R. 2843: STOP GAMES Act of 2021 - Provisions related to citizen petitions H.R. 2869: Increasing Access to Biosimilars Act of 2021 - Provisions related to biosimilars and prescription drug pricing H.R. 2883: Stop Stalling Access to Affordable Medications - Provisions related to citizen petitions H.R. 3761: Promising Pathways Act - Provisions related to FDA policy H.R. 3932: PASTEUR Act of 2021 - Provisions related to antimicrobial resistance policy issues H.R. 4390: PROTECT 340B Act of 2021 - Provisions related to 340B drug discount program H.R. 4418: SPIKE Act - Provisions related to prescription drug pricing transparency H.R. 5030: DIVERSE Trials Act - To improve diversity in clinical trials and data collection for COVID-19 and future public health threats to address social determinants of health H.R. 5416: To amend the Federal Food, Drug, and Cosmetic Act to establish additional authorities of the Food and Drug Administration regarding the conduct of pediatric investigations of molecularly targeted drugs to treat cancer, and for other purposes S. 154: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2021- Provisions related to FDA drug approval process S. 164: Advancing Education on Biosimilars Act of 2021 - Provisions related to biologics and biosimilar products S. 259: Safe and Affordable Drugs from Canada Act of 2021 - Provisions related to prescription drug importation S. 562: Ensuring Timely Access to Generics Act of 2021 - Provisions related to citizen petitions S. 773: A bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes - Provisions related to 340B drug discount program S. 917: Short on Competition Act - Provisions related to FDA policy and prescription drug pricing S. 920: Affordable and Safe Prescription Drug Importation Act - Provisions related to prescription drug importation S. 1425: Stop STALLING Act - Provisions related to citizen petitions S. 1427: Increasing Access to Biosimilars Act of 2021 - Provisions related to biosimilars and prescription drug pricing S. 1462: Simplifying the Generic Drug Application Process Act - Provisions related to FDA policy and approvals S. 1644: Promising Pathway Act - Provisions related to FDA policy S. 1645: ADAPT Act - Provisions related to FDA policy S. 2076: PASTEUR Act of 2021 - Provisions related to antimicrobial resistance policy issues S. 2428: False Claims Amendments Act of 2021 - Provisions related to False Claims Act S. 2429: Administrative False Claims Act of 2021 - Provisions related to False Claims Act S. 2706: DIVERSE Trials Act - Provisions related to FDA policy S. 2814: Vital Medication Affordability Act - Provisions related to 340B drug discount program S. 2837: 340B Accountability Act of 2021 - Provisions related to 340B drug discount program 21st Century Cures 2.0 (discussion draft) American Jobs Plan RFI for Advanced Research Projects Agency - Health (ARPA-H) HHS PREP Act declaration relating to COVID-19 Drug cost and pricing policy issues Principles for drug pricing reform Drug importation policy issues Drug counterfeiting policy issues PDUFA reauthorization BsUFA reauthorization Competition policy issues Health Advanced Research Projects Agency (HARPA) proposal Expanded access policy issues Antimicrobial resistance (AMR) policy issues High deductible health plans/HSA policy issues Supply chain and foreign manufacturing policy issues Real world evidence policy issues Clinical trial diversity policy issues FDA modernization policy issues 340B drug discount program policy issues Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues Regulatory efficiencies policy issues COVID-19 policy issues Defense Production Act (DPA) policy issues Proposed Rule; Most Favored Nation (MFN) Model (proposes to rescind the Most Favored Nation Model interim final rule with comment period) Final Rule; Importation of Prescription Drugs Executive Order 14036, Promoting Competitition in the American Economy (July 9, 2021) Executive Order 14017, Americas Supply Chains (February 24, 2021) Executive Order 14005, Ensuring the Future Is Made in All of America by All of Americas Workers (January 25, 2021) Executive Order 14001 on a Sustainable Public Health Supply Chain (January 21, 2021) Executive Order 13987, Organizing and Mobilizing the United States Government To Provide a Unified and Effective Response To Combat COVID-19 and To Provide United States Leadership on Global Health and Security (January 20, 2021) Buy America and other associated issues related to procurement and sourcing of finished product and active pharmaceutical ingredients
2021 · third_quarter · Taxation/Internal Revenue Code
The reduction, stabilization and/or change of the tax credit for the Orphan Drug Act and how it affects plasma protein therapies and their innovation, also H.R. 2623.
Client expense: $140,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS)
2021 · second_quarter · Taxation/Internal Revenue Code
HR 2623: CAMERON'S LAW; ALL PROVISIONS OF THE BILL
Client expense: $190,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Client expense: $7,440,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE